BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27568917)

  • 1. Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.
    Kopalli SR; Kang TB; Koppula S
    Expert Opin Ther Pat; 2016 Nov; 26(11):1239-1256. PubMed ID: 27568917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of necroptosis in the treatment of diseases.
    Cho YS
    BMB Rep; 2018 May; 51(5):219-224. PubMed ID: 29636122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear factor-kappa B inhibitors; a patent review (2006-2010).
    Kwak JH; Jung JK; Lee H
    Expert Opin Ther Pat; 2011 Dec; 21(12):1897-910. PubMed ID: 22098320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serine protease inhibitors to treat inflammation: a patent review (2011-2016).
    Soualmia F; El Amri C
    Expert Opin Ther Pat; 2018 Feb; 28(2):93-110. PubMed ID: 29171765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of RIP1 kinase: a patent review (2016-present).
    Harris PA
    Expert Opin Ther Pat; 2021 Feb; 31(2):137-151. PubMed ID: 33249869
    [No Abstract]   [Full Text] [Related]  

  • 6. Critical contribution of oxidative stress to TNFα-induced necroptosis downstream of RIPK1 activation.
    Shindo R; Kakehashi H; Okumura K; Kumagai Y; Nakano H
    Biochem Biophys Res Commun; 2013 Jun; 436(2):212-6. PubMed ID: 23727581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Contribution of Necroptosis in Neurodegenerative Diseases.
    Shao L; Yu S; Ji W; Li H; Gao Y
    Neurochem Res; 2017 Aug; 42(8):2117-2126. PubMed ID: 28382594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TBK1 inhibitors: a review of patent literature (2011 - 2014).
    Yu T; Yang Y; Yin DQ; Hong S; Son YJ; Kim JH; Cho JY
    Expert Opin Ther Pat; 2015; 25(12):1385-96. PubMed ID: 26293650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present).
    Xu L; Zhang W; Zhuang C
    Expert Opin Ther Pat; 2023 Feb; 33(2):101-124. PubMed ID: 36960668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic exploitation of necroptosis for cancer therapy.
    Fulda S
    Semin Cell Dev Biol; 2014 Nov; 35():51-6. PubMed ID: 25065969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of necroptosis, an alternative form of cell death, in cancer therapy.
    Yu X; Deng Q; Bode AM; Dong Z; Cao Y
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):883-93. PubMed ID: 23875666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Necroptosis: Modules and molecular switches with therapeutic implications.
    Arora D; Sharma PK; Siddiqui MH; Shukla Y
    Biochimie; 2017 Jun; 137():35-45. PubMed ID: 28263777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using drugs to target necroptosis: dual roles in disease therapy.
    Wang Z; Guo LM; Zhou HK; Qu HK; Wang SC; Liu FX; Chen D; Huang JF; Xiong K
    Histol Histopathol; 2018 Aug; 33(8):773-789. PubMed ID: 29393502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis.
    Philipp S; Sosna J; Plenge J; Kalthoff H; Adam D
    Cell Commun Signal; 2015 Apr; 13():25. PubMed ID: 25925126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Itk inhibitors: a patent review.
    Lo HY
    Expert Opin Ther Pat; 2010 Apr; 20(4):459-69. PubMed ID: 20218931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress on necroptosis regulation mechanism and its clinical relevance].
    Wang XX; Liu XQ; Zhao L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1025-9. PubMed ID: 22931677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical regulation of signaling pathways to programmed necrosis.
    Bae JH; Shim JH; Cho YS
    Arch Pharm Res; 2014 Jun; 37(6):689-97. PubMed ID: 24715577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Necroptosis in cardiovascular disease - a new therapeutic target.
    Gupta K; Phan N; Wang Q; Liu B
    J Mol Cell Cardiol; 2018 May; 118():26-35. PubMed ID: 29524460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potentials of selected therapeutic targets for inflammation: a snapshot.
    Nayadu S; Kaur G; Gudi G; Addepalli V
    Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):137-46. PubMed ID: 22432894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vivo significance of necroptosis: lessons from exploration of caspase-8 function.
    Wallach D; Kang TB; Yang SH; Kovalenko A
    Cytokine Growth Factor Rev; 2014 Apr; 25(2):157-65. PubMed ID: 24411566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.